CFTR and cystic fibrosis: Due to its favorable safety profile and pharmacokinetic (PK) properties in rats (including low CYP3A4 induction, low clearance, and a long half-life), combined with its acceptable potency and efficacy the 2-(dimethylamino)-3-pyridyl analog 15 emerged as a promising type 2 corrector to be used in modulator combination therapies aimed at targeting CFTR processing defects in CF [131].